Status:
TERMINATED
Efficacy and Safety of Alflorex Bei Reizdarm in Patients With Irritable Bowel Syndrome
Lead Sponsor:
Medice Arzneimittel Pütter GmbH & Co KG
Collaborating Sponsors:
BioTeSys GmbH
Conditions:
Irritable Bowel Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
This Post-Market Clinical-Follow Up (PMCF) study gains data on the efficacy and safety of "Alflorex bei Reizdarm", a probiotic based on Bifidobacterium longum 35624, in the daily use by irritable bowe...
Detailed Description
This Post-Market Clinical-Follow Up (PMCF) study observes adult patients with irritable bowel syndrome (IBS) which receive "Alflorex bei Reizdarm", a probiotic based on Bifidobacterium longum 35624, f...
Eligibility Criteria
Inclusion
- Adult, diagnosed IBS patients with typical IBS symptoms (abdominal pain, bloating, gas, constipation or diarrhea) and physician's recommendation to take the study medication (probiotic with B. longum 35624) for 8 weeks
Exclusion
- \-
Key Trial Info
Start Date :
May 5 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 9 2021
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT04859075
Start Date
May 5 2021
End Date
November 9 2021
Last Update
January 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Several General Practicioner and Gastroenterologists (Multicentric)
Düsseldorf, North Rhine-Westphalia, Germany